A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

NCT05562830 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

BIOLOGICAL: Zilovertamab vedotin
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: MK-3120

Sponsor

Merck Sharp & Dohme LLC